the outcome of autologous stem cell transplantation in first complete remission acute myeloid leukemia patients- single center study

post-remission treatment in patients with acute myeloid leukemia is still controversial. one potent choice for patients with no donor available is autologous stem cell transplantation. the median follow-up period was 18 months and the median age was 26 years old. in the review of 116 recently diagnosed aml patients (except aml- m3) who underwent autologous stem cell transplantation, 72.4% of patients remained alive and 27.6% relapsed. relapse was the most common causes of death in patients. the one- year os and dfs of patients was 73.8% and 59.8%, respectively. there was no statistically significant difference between age, sexuality and waiting time from diagnosis to transplantation. for more comprehensive results, longer follow- up is required.